Opthea Ltd (ASX: OPT) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Opthea Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $849.46 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 1.23 billion
Earnings per share -0.345
Dividend per share N/A
Year To Date Return 31.43%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Opthea Ltd (ASX: OPT)
    Latest News

    a woman
    Share Gainers

    Why Althea, Northern Star, Opthea, & Suncorp shares raced higher today

    The Opthea Ltd (ASX:OPT) share price and the Suncorp Group Ltd (ASX:SUN) share price are two of four racing notably…

    Read more »

    a woman
    Share Gainers

    Why the Opthea share price could zoom higher today

    The Opthea Ltd (ASX:OPT) share price could zoom higher today following the release of a positive study result...

    Read more »

    a woman
    ⏸️ Investing

    5 ASX shares to build a portfolio around

    Here are my five “must have” stocks picks for those looking to build a well-diversified portfolio that can deliver long-term…

    Read more »

    a woman
    Share Gainers

    These small cap ASX shares have pushed higher on Wednesday

    The ResApp Health Ltd (ASX:RAP) share price is one of three pushing higher on Wednesday. Here's why...

    Read more »

    a woman
    Healthcare Shares

    Can Opthea Ltd (ASX:OPT) be the next Cochlear Limited (ASX:COH)?

    Shares in Cochlear Limited (ASX: COH) have almost quadrupled in price over the last 4 years. Can young healthcare company…

    Read more »

    a woman
    Share Gainers

    These 3 small cap ASX shares are on the rise on Friday

    The Opthea Ltd (ASX:OPT) share price is one of three on the rise in the small cap space on Friday.…

    Read more »

    a woman
    ⏸️ Investing

    Are these 3 ASX shares the next biotech blockbusters?

    Here are three shares that are looking to follow in the footsteps of $60 billion biotech giant CSL Limited (ASX:CSL)…

    Read more »

    a woman
    ⏸️ Investing

    Here are 3 exciting biotech shares for growth investors

    Here are three fledgling biotech shares aiming to be the next CSL Limited (ASX:CSL)…

    Read more »

    a woman
    ⏸️ Investing

    These 3 ASX shares just stormed to all-time highs: Can they go higher?

    The AGL Energy Ltd (ASX:AGL) share price is one of three that have stormed to all-time highs. Here’s why…

    Read more »

    a woman
    ⏸️ Investing

    Why the Opthea Ltd share price rocketed 38% today

    The Opthea Ltd (ASX:OPT) share price has been a huge mover on the market today. Here’s why it rocketed 38%...

    Read more »

    Frequently Asked Questions

    No, Opthea does not pay shareholder dividends at this time.

    Opthea Limited listed on the ASX on 18 April 1991. 

    OPT ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Opthea Ltd

    Opthea Limited (ASX: OPT) is a biopharmaceutical company specialising in the development of biological therapeutics for retinal eye diseases. The company is developing a novel therapy, OPT-302, designed to be used in combination with existing therapies. OPT-302, the company's leading drug candidate, has the potential to address wet age-related macular degeneration (AMD) and diabetic macular edema (DME) in patients. It is currently at Phase 3 clinical trial stage. 

    OPT Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    20 Dec 2024 $0.69 $0.03 4.55% 2,072,011 $0.67 $0.71 $0.67
    19 Dec 2024 $0.66 $0.01 1.54% 1,316,965 $0.64 $0.68 $0.61
    18 Dec 2024 $0.65 $0.02 3.15% 1,330,226 $0.64 $0.66 $0.63
    17 Dec 2024 $0.64 $0.00 0.00% 1,310,854 $0.64 $0.65 $0.63
    16 Dec 2024 $0.64 $0.01 1.59% 1,344,097 $0.63 $0.64 $0.62
    13 Dec 2024 $0.63 $-0.02 -3.10% 670,680 $0.64 $0.64 $0.62
    12 Dec 2024 $0.65 $-0.03 -4.48% 1,198,499 $0.67 $0.68 $0.63
    11 Dec 2024 $0.67 $-0.02 -2.88% 860,119 $0.70 $0.70 $0.67
    10 Dec 2024 $0.70 $-0.01 -1.42% 2,219,565 $0.70 $0.71 $0.66
    09 Dec 2024 $0.71 $-0.02 -2.78% 501,610 $0.71 $0.74 $0.71
    06 Dec 2024 $0.72 $0.02 2.84% 830,460 $0.71 $0.74 $0.71
    05 Dec 2024 $0.71 $-0.01 -1.40% 1,067,298 $0.71 $0.74 $0.70
    04 Dec 2024 $0.72 $-0.03 -4.05% 754,820 $0.74 $0.75 $0.71
    03 Dec 2024 $0.74 $0.04 5.67% 1,099,817 $0.73 $0.75 $0.71
    02 Dec 2024 $0.71 $-0.02 -2.78% 2,600,065 $0.74 $0.75 $0.70
    29 Nov 2024 $0.72 $0.04 5.88% 2,450,432 $0.70 $0.72 $0.70
    28 Nov 2024 $0.68 $0.04 6.20% 2,346,589 $0.65 $0.70 $0.64
    27 Nov 2024 $0.65 $0.01 1.56% 3,134,621 $0.64 $0.65 $0.62
    26 Nov 2024 $0.64 $0.03 4.92% 4,169,617 $0.62 $0.65 $0.60
    25 Nov 2024 $0.61 $0.01 1.65% 2,068,964 $0.61 $0.63 $0.60
    22 Nov 2024 $0.61 $-0.02 -3.20% 1,666,247 $0.62 $0.63 $0.60

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    17 Dec 2024 Lawrence Gozlan Issued 2,000,000 $1,270,000
    Issue of options.
    17 Dec 2024 Anshul Thakral Issued 2,000,000 $1,270,000
    Issue of options.
    17 Dec 2024 Lawrence Gozlan Expiry 2,000,000 $1,270,000
    Options expired.
    17 Dec 2024 Quinton Oswald Issued 2,000,000 $1,270,000
    Issue of options. As per announcement on 17-12-2024
    17 Dec 2024 Susan Orr Issued 2,000,000 $1,270,000
    Issue of options. As per announcement on 17-12-2024
    17 Dec 2024 Jeremy Levin Issued 2,000,000 $1,270,000
    Issue of options.
    17 Dec 2024 Sujal Shah Issued 2,000,000 $1,270,000
    Issue of options.
    17 Dec 2024 Julia Haller Issued 1,000,000 $635,000
    Issue of options.
    01 Mar 2024 Megan Baldwin Sell 3,012,277 $1,656,752
    As advised by the company. Sale of 3,012,277 ordinary shares to cover
    personal tax obligations
    01 Mar 2024 Megan Baldwin Sell 987,723 $543,247
    As advised by the company. Sale of 987,723 ordinary shares to cover
    personal tax obligations
    21 Dec 2023 Lawrence Gozlan Issued 500,000 $235,000
    Issue of options. As per announcement on 21-12-2023
    21 Dec 2023 Megan Baldwin Issued 3,000,000 $1,410,000
    Issue of options.
    21 Dec 2023 Jeremy Levin Issued 3,000,000 $1,410,000
    Issue of options.
    21 Dec 2023 Anshul Thakral Issued 1,000,000 $470,000
    Issue of options.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Lawrence Bernard Gozlan Non-Executive Director Jul 2020
    Mr. Gozlan, a biotechnology investor and advisor, is the Life Sciences Investment Manager at Jagen Pty Ltd, an international private investment organization. Mr. Gozlan is also the Chief Investment Officer and Founder of Scientia Capital, a global investment fund focused exclusively on life sciences. Scientia was founded to provide expertise and to manage investments for high net worth individuals, family offices and institutional investors wanting exposure to the life sciences industry. Prior to this, Mr. Gozlan was responsible for the biotechnology investment portfolio in Australia as the institutional biotechnology analyst at QIC (the Queensland Investment Corporation), an investment fund with over $60 billion under management. He previously worked as the senior biotechnology analyst in the equities team at Foster Stockbroking, and gained senior corporate finance experience advising life science companies at Deloitte.
    Dr Jeremy Levin Non-Executive ChairmanNon-Executive Director Oct 2020
    Dr. Levin has served as the Chief Executive Officer of Ovid Therapeutics Inc. since 2015, and since 2014, as Chairperson of the board of directors, of Ovid. From May 2012 to October 2013, Dr. Levin served as the President and Chief Executive Officer of Teva Pharmaceutical Industries Ltd., a publicly held pharmaceutical company. From September 2007 to December 2012, Dr. Levin held several roles at Bristol Myers Squibb Company, a publicly held pharmaceutical company, ultimately serving as the Senior Vice President of Strategy, Alliances and Transactions. Dr. Levin also served as a member of the executive committee at Bristol Myers Squibb Company.
    Dr Julia Haller Non-Executive Director Jun 2021
    Dr. Haller, since 2007, has served as Ophthalmologist in Chief and William Tasman MD Endowed Chair at Wills Eye Hospital in Philadelphia. She is Professor and Chair of the Department of Ophthalmology at the Sidney Kimmel Medical College at Thomas Jefferson University as well as a Director of Bristol Myers Squibb and Outlook Therapeutics. She is a member of the National Academy of Medicine, the Chair of the College of Physicians of Philadelphia, Chair of the Heed Ophthalmic Society, past president of the Women in Medicine Legacy Foundation, and serves on several boards including the board of the John Hopkins Medical and Surgical Association, the Association of University Professors of Ophthalmology, and the Society of Heed Fellows. Dr Haller is member of Clinical/Research and Development committee.
    Dr Susan Orr Non-Executive Director Apr 2022
    Dr. Orr is an experienced medical and business leader with specialization in identifying, developing and commercializing ophthalmic therapeutic product candidates. Dr. Orr currently serves as the Chief Medical Officer at Claris Biotherapeutics and is a member of the Retina Global Board of Directors. Before Claris, Dr. Orr was the Chief Executive Officer at Notal Vision subsequent to joining the company as Chief Medical Officer. Dr. Orr has spent more than 30 years in the field of ophthalmology that also includes ten years in private optometric practice and leadership roles at Alcon and Janssen spanning international development, global new product strategy, and business development and licensing. Dr. Orr participated in acquisitions including Durezol and Beovu (brolucizumab) and has been a Managing Partner at Fovenedeye Consulting since 2016. Dr Susan is member of Risk Committee and chair of Clinical/Research and Development committee.
    Mr Quinton Oswald Non-Executive Director Apr 2022
    Mr. Oswald brings over 25 years of international general management experience, including onsite assignments in the US, Europe and South Africa. Most recently, he was the CEO of Notal Vision, a commercial stage ophthalmic home monitoring services provider with a focus on both wet and dry AMD. Prior to Notal Vision, he served as the CEO of Neurotech and, prior to that, as the CEO of SARcode Bioscience, where he was in the clinical development of lifitegrast ophthalmic solution 5 percent (Xiidra) for the treatment of dry eye disease, and its subsequent sale to Shire, PLC. Previously, he was Vice President and Business Unit Head for Genentech's tissue growth and repair business. During his tenure at Genentech, Mr. Oswald oversaw the commercial launch of Lucentis (ranibizumab) for the treatment of wet AMD. Before Genentech, Mr. Oswald led the North American Ophthalmology business for Novartis, which, in conjunction with QLT, Inc., pioneered Visudyne. Mr. Oswald is member of Risk Committee and Clinical/Research and Development committee.
    Mr Anshul Thakral Non-Executive Director Jun 2023
    Mr. Thakral is Chief Executive Officer and Board Member of Launch Therapeutics, a clinical development company backed by funds managed by global investment firm Carlyle and its life sciences franchise, Abingworth. Mr. Thakral has worked for over 20 years in the pharmaceutical and biotechnology industry and is an experienced executive, management consultant and entrepreneur. Mr. Thakral was previously Chief Commercial Officer and Executive Vice President of Peri and Post Approval Services at PPD, and prior to that was Global Head of PPD Biotech. Before PPD, Mr. Thakral ran the global life sciences business unit at Gerson Lehrman Group and worked at McKinsey & Company as an associate principal in the health care practice, where he provided strategic advice to global pharmaceutical and biotechnology companies on growth, research and development, business development and commercialization. He currently serves on the boards of TriNetX, Saama Technologies, Orsini Specialty Pharmacy, is an Operating Executive at Carlyle and is a Venture Partner at Abingworth. He is member of Clinical/Research and Development committee.
    Mr Sujal Arun Shah Non-Executive Director Apr 2024
    Mr. Shah is a biopharmaceutical executive with leadership and product development experience and a track record in capital formation that complements the expertise in retinal disease, especially wet AMD, of the Opthea Board. Most recently, Mr. Shah served as President and Chief Executive Officer of CymaBay Therapeutics which was acquired by Gilead Sciences for approximately $4.3 billion in total equity value in March 2024. Mr Sujal is chair of Risk Committee.
    Ms Katherine(Kathy) Ellen Danielle Connell Non-Executive Director Nov 2024
    Ms Connell is a commercial executive with business development expertise across pharmaceutical, vaccine, medtech, consumer and digital health industries. Her track record of translating global commercial strategies into impactful business results and shareholder value will be instrumental as Opthea prepares for the topline data readout of its pivotal program of sozinibercept in wet AMD. Ms. Connell is currently Senior Client Partner and Head of Healthcare and Life Sciences Australia/New Zealand at Korn Ferry. She also serves as Non-Executive Director at Avecho Biotechnology Ltd (ASX: AVE), Proto Axiom (a biotech investment company with an incubation arm) and BioNSW (life sciences association for NSW, Australia).
    Mrs Karen Adams Company SecretaryVice President of Finance Jun 2021
    -
    Dr Frederic Guerard Chief Executive Officer Oct 2023
    -
    Judith Robertson Chief Commercial Officer
    -
    Frederic Guerard Chief Executive Officer
    -
    Peter Lang Chief Financial Officer
    -
    Karen Adams Company SecretaryVice President of Finance
    -
    Fang Li Senior Vice President Regulatory Affairs
    -
    Julie Clark Senior Vice President of Clinical Development
    -
    Bruno Gagnon Senior Vice President Global Clinical Operations
    -
    Mark O'Neill Vice President CMC
    -
    John Han Vice President Medical Affairs
    -
    Kevin Bitter Vice President Strategy & Corporate Development
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Citicorp Nominees Pty Limited 180,041,041 14.62%
    UBS Nominees Pty Ltd 164,238,358 13.34%
    HSBC Custody Nominees (Australia) Limited 151,845,051 12.33%
    JP Morgan Nominees Australia Pty Limited 151,418,346 12.30%
    BNP Paribas Noms Pty Ltd 64,844,903 5.27%
    HSBC Custody Nominees(Australia) Limited-Gsco Eda 60,000,000 4.87%
    National Nominees Limited 52,933,500 4.30%
    HSBC Custody Nominees (Australia) Limited-Gsi Eda 43,877,058 3.56%
    Merrill Lynch(Australia) Nominees Pty Limited 42,764,892 3.47%
    HSBC Custody Nominees (Australia) Limited A/C2 22,785,116 1.85%
    Neweconomy Com Au Nominees Pty Limited <900 Account> 16,402,937 1.33%
    Jagen Pty Ltd 13,755,397 1.12%
    Est Ms Margaret Lynette Harvey 13,162,671 1.07%
    HSBC Custody Nominees(Australia) Limited <Nt Comnwlth Super Corp A/C> 12,420,253 1.01%
    Buttonwood Nominees Pty Ltd 11,311,250 0.92%
    Jadeglen Investments Pty Ltd <David Thurin Family A/C> i 9,004,711 0.73%
    Safo Investments Pty Ltd<Safo Investment A/C> 8,134,875 0.66%
    BNP Paribas Noms (Nz) Ltd 6,840,745 0.56%
    Armada Trading Pty Limited 5,005,806 0.41%
    Jadeglen Investments Pty Ltd <David Thurin Family A/C> ii 5,000,000 0.41%

    Profile

    since

    Note